My Cart
You have no items in your shopping cart.
Background
The human KCNA1 gene encodes the pore-forming subunit of Kv1.1, a voltage-gated potassium channel. Mutations in KCNA1 cause several congenital disorders including episodic ataxia type 1, neuromyotonia, and autosomal dominant hypomagnesia. Kv1.1 channels expressed in neurons are therapeutic targets in multiple sclerosis, stroke and seizure.
| General Info | |
| Product Description | Human Kv1.1 potassium ion channel-expressing, stable replicating cell line. |
|---|---|
| Target Type | Ion Channel |
| Product Type | Replicating Cell Line |
| Family | Potassium, Voltage-Gated |
| Sub-Type | Kv1.1 |
| Class | Voltage-gated potassium channel |
| Therapeutic Area | neurodegeneration & stroke |
| Related Services | Large-scale Cryopreservation |
| Gene Name | KCNA1 |
| Validated Assay/Platform | IonWorks Quattro™, PatchXpress®, QPatch HT |
| References | Gutman GA, et al. 2005. Pharmacol Rev. 57:473-508. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. |
| Host cell | HEK293 |
| Mycoplasma Status | Negative (MycoAlert Kit) |
| Storage & Packaging | |
| Packaging | Cryopreserved cells, 1-2x106 cells |
| Storage Recommendation | liquid nitrogen |
| Quantity | 1-2 million cells |
| Product Documentation | |
| Specification Sheet |  Download PDF Document |
